You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
天境生物(IMAB.US)將與Bristol Myers Squibb合作評估Givastomig在胃癌和食管癌中的聯合使用
格隆匯 06-05 19:46

格隆匯6月5日丨天境生物(IMAB.US)公佈,2024年6月5日公司已與Bristol Myers Squibb(NYSE: BMY)簽訂了臨牀試驗合作和供應協議。該合作將評估Givastomig(一種由I-Mab和ABL Bio((KOSDAQ:298380)共同開發的針對Claudin18.2x4-1BB雙特異性抗體)Bristol Myers Squibb的免疫檢查點抑制劑nivolumab以及化療(FOLFOX或CAPOX)聯合使用,作為晚期Claudin18.2陽性胃癌和食管癌患者的潛在一線治療方案。根據協議條款,該研究將由I-Mab進行的多國I期研究。Bristol Myers Squibb將提供nivolumab。Nivolumab是一種免疫檢查點抑制劑,旨在阻止癌細胞上的PD-L1蛋白與PD-1結合,增強T細胞功能,從而提高抗腫瘤反應。

I-Mab首席執行官Raj Kannan表示:"我們很高興與Bristol Myers Squibb簽訂這項臨牀合作協議,因為我們將進入givastomig開發的下一個階段,探索這種雙特異性抗體在三聯療法中的顯著潛力。該研究基於我們在2023年ESMO會議上展示的givastomig作為單一藥物的鼓舞人心的活動和安全性。我們仍然樂觀地認為,givastomig與nivolumab和化療的聯合使用將在特定腫瘤中驅動強大的抗腫瘤活性,我們期待在臨牀研究中加速進展。"

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account